Abstracts tagged "patient outcomes"

Abstract Number: 1599 • 2016 ACR/ARHP Annual Meeting
Speed of Onset of Effect on Patient-Reported Outcomes Assessed through Daily Electronic Patient Diaries in the Baricitinib Phase 3 RA Clinical Program
Peter C. Taylor¹, Grace C. Wright², Carol L. Gaich³, Amy M. DeLozier³, Stephanie de Bono³, Douglas E. Schlichting³, Terence Rooney³, Jiajun Liu³, Scott D. Beattie⁴ and Maxime Dougados⁵, ¹NDORMS, University of Oxford, Oxford, United Kingdom, ²NYU Langone Medical Center, New York, NM, ³Eli Lilly and Company, Indianapolis, IN, ⁴Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, ⁵Dept of Rheumatology, Cochin Hospital, Paris, France
Background/Purpose: Baricitinib (bari), an oral Janus kinase (JAK) 1/JAK2 selective inhibitor, has demonstrated clinical efficacy with a satisfactory safety profile when administered once daily in…
Abstract Number: 1689 • 2016 ACR/ARHP Annual Meeting
Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Alice B. Gottlieb¹, M. Elaine Husni², Catherine L. Shuler³, Russel T. Burge³, Chen-Yen Lin³, Chin H. Lee³ and D Gladman⁴, ¹Tufts University School of Medicine, Boston, MA, ²Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: PsA has a negative impact on patients’ quality of life, physical function, and work productivity. Ixekizumab (IXE) is an IgG4 mAb that binds with…
Abstract Number: 1692 • 2016 ACR/ARHP Annual Meeting
Validation of a Two-Question Patient Reported Outcome Measure for Psoriasis
Jessica Mounessa¹, Darren Lynn¹, Jessica Walsh², Mena Hashim¹, Ryan Duong³, Robert Dellavalle¹ and Liron Caplan¹, ¹Denver Veterans Affairs Medical Center and UC Denver SOM, Denver, CO, ²Division of Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ³Rheumatology, Denver Veterans Affairs Medical Center and UC Denver SOM, Denver, CO
Background/Purpose: While the psoriasis area and severity index (PASI) is the most commonly used assessment tool for psoriasis severity, it has been criticized for its…
Abstract Number: 2003 • 2016 ACR/ARHP Annual Meeting
Validation of the ASAS Health Index: Results of a Multicenter International Study in 23 Countries
Uta Kiltz¹, Désirée van der Heijde², Annelies Boonen³, Jürgen Braun¹ and ASAS HI international validation study, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: The ASAS Health Index (ASAS HI) was developed to measure functioning and health in patients with spondyloarthritis (SpA) aiming to better define the impact…
Abstract Number: 95 • 2016 ACR/ARHP Annual Meeting
An Analysis of Malpractice Litigation in Rheumatology
Arpan Prabhu¹, Raghav Gupta², Ranjit Thomas³ and Chester V. Oddis⁴, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²Rutgers New Jersey Medical School, Newark, NJ, ³Tufts University, Medford, MA, ⁴Rheumatology/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Medicine is an increasingly more litigious environment, and the probability of a practitioner facing a medical malpractice claim is high. Given the tumultuous liability…
Abstract Number: 2041 • 2016 ACR/ARHP Annual Meeting
Validity and Reliability of Patient Reported Outcomes Measurement Information System (PROMIS®) Global Health Short Form in Patients with SLE
Shanthini Kasturi¹, Jayme C. Burket², Jessica Berman¹, Kyriakos A. Kirou¹, Alana B. Levine¹, Lisa R. Sammaritano¹ and Lisa Mandl¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Healthcare Research Institute, Hospital for Special Surgery, New York, NY
Background/Purpose: The measurement of patient reported outcomes (PROs) is a growing priority for performance improvement in clinical care of chronic conditions such as SLE. Measuring…
Abstract Number: 100 • 2016 ACR/ARHP Annual Meeting
Patient Support Program for Adalimumab-Treated Patients in Brazil: Impact on Patients’ Adherence and Persistence
Roger A. Levy¹, Vanessa Teich², Roberta Fernandes², Anna Gulart², Leonardo Chaves³, Vishvas Garg⁴ and Martha Skup⁵, ¹Rheumatology, Department of Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Sense Company, São Paulo, Brazil, ³AbbVie Inc., Chicago, IL, ⁴AbbVie Inc, North Chicago, IL, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: The Brazilian public healthcare system covers treatment with adalimumab for rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriatic arthritis, in line with local guidelines.…
Abstract Number: 2250 • 2016 ACR/ARHP Annual Meeting
A Real World View of Rheumatoid Arthritis Patients Treated with Advanced Therapies: Comparing Patient Profiles and Outcomes
Laurent Chanroux and Fara Mboge, Therapy Watch, Research Partnership, London, United Kingdom
Background/Purpose: Advanced therapies including bDMARDs and tofacitinib have been shown to help control disease progression in rheumatoid arthritis (RA) and reduce joint damage. The aim…
Abstract Number: 679 • 2015 ACR/ARHP Annual Meeting
Patients with Psoriatic Arthritis and Oligoarthritic Subtype Report Higher Disease Burden Than Patients with a Polyarthritic Pattern – Data from the German Collaborative Arthritis Centres
Dörte Huscher¹, Katinka Albrecht², Sascha Bischoff², Katja Thiele², Frank Behrens³, Kathrin Fischer⁴, Ulrich von Hinüber⁵, Susanna Späthling-Mestekemper⁶, Siegfried Wassenberg⁷ and Angela Zink¹, ¹German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, ⁴Praxis fuer Innere Medizin, Aerztehaus Schoenwalde, Greifswald, Germany, ⁵Practice-based rheumatologist, Hildesheim, Germany, ⁶Practice-based rheumatologist, München, Germany, ⁷Rheumaklinik, Themistocles Gluck hospital - Rheumazentrum Ratingen, Ratingen, Germany
Background/Purpose: Psoriatic arthritis (PsA) divides into different subtypes, of which polyarthritis and spondylitis would be expected with the highest disease severity. We compared disease burden…
Abstract Number: 682 • 2015 ACR/ARHP Annual Meeting
Misalignment Between Physician and Patient Satisfaction with Current Psoriatic Arthritis Treatment
Daniel E. Furst¹, Emma Sullivan², James Pike³, James Piercy⁴, Jacqueline Palmer⁵ and Vivian Herrera⁵, ¹Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Adelphi Real World, Manchester, United Kingdom, ³Statistics, Adelphi Real World, Macclesfield, United Kingdom, ⁴Adelphi Real World, Macclesfield, United Kingdom, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic Arthritis (PsA) is a chronic immune related condition affecting the joints and commonly occurs alongside psoriasis. Well-established physician patient relationships are instrumental to…
Abstract Number: 1746 • 2015 ACR/ARHP Annual Meeting
Patient’s Ability of Coping Is Influencing the Correlation Between Clinical and Ultrasonographic Evidence of Disease Activity in Psoriatic Arthritis
Brigitte Michelsen¹, Andreas P Diamantopoulos^1,2, Hilde Berner Hammer³, Dag Magnar Soldal⁴, Arthur Kavanaugh⁵ and Glenn Haugeberg^1,6,7, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Rheumatology, Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁵University of California, San Diego School of Medicine, LaJolla, CA, ⁶Rheumatology, Martina Hansens Hospital, Gjettum, Norway, ⁷Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: Coping may be defined as the set of adaptive processes a patient uses to live well with aspects of disease such as pain. Coping…
Abstract Number: 1974 • 2015 ACR/ARHP Annual Meeting
Do Patients with Giant Cell Arteritis Meet the 2011 United Kingdom Department of Health Guidance on Physical Activity?
Joanna Robson¹, Karolina Lada², Anne Miller³, Wilby Williamson¹, Julia Newton² and Raashid Luqmani⁴, ¹Rheumatology, University of Oxford, Oxford, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³Nuffield Orthopaedic Center, Oxford., Oxford, United Kingdom, ⁴Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Physical inactivity is the fourth leading risk factor for global mortality accounting for 6% of deaths. Patients with giant cell arteritis (GCA) are at…
Abstract Number: 2327 • 2015 ACR/ARHP Annual Meeting
Documentation of Clinical Improvement in Patient with Polymyalgia Rheumatica According to MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data): Longitudinal Analysis from Routine Care
Isabel Castrejón¹, Annie Huang¹, Sarah L. Everakes², Ailda Nika¹, Winston Sequeira¹ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Internal Medicine, Rush University Medical Center, Chicago, IL
Background/Purpose: RAPID3 is an index found on the MDHAQ, which is effective in rheumatoid arthritis (RA) clinical trials and clinical care (1). MDHAQ/RAPID3 also is…
Abstract Number: 2493 • 2015 ACR/ARHP Annual Meeting
Improvement of Disease Activity and Quality of Care in a Cohort of Rheumatoid Arthritis Patients Treated with Conventional Dmard Therapy Under Treat to Target Recommendations and a Model of Patient-Centered Care
Pedro Ivan Santos-Moreno¹, Ginna Saavedra², Rosana Ramirez², Laura Villarreal², Ana Bolena Cardozo², Vanessa Giraldo², Paola Martinez², Adriana Sanchez², Merle Sanchez², Danny Gomez² and Juan Manuel Bello², ¹Rheumatology, Biomab, Center for Rheumatoid Arthritis., Bogota, Colombia, ²Rheumatology, Biomab, Center for Rheumatoid Arthritis, Bogota, Colombia, Bogota, Colombia
Background/Purpose: Treat to Target (T2T) strategy becomes from the need to develop therapeutic targets and tools to achieve defined outcomes in rheumatoid arthritis (RA). Moreover,…
Abstract Number: 2640 • 2015 ACR/ARHP Annual Meeting
Factors Influencing Treatment Adjustments in RA Patients – Biologic DMARD Treatment Start and Options
Peter C. Taylor¹, Emma Sullivan², Robert Wood³, James Piercy³, Rieke Alten⁴, Juan J Gomez-Reino⁵, Philippe Bertin⁶, Roberto Caporali⁷, Radu Vasilescu⁸, Dean Spurden⁹ and Jose Alvir¹⁰, ¹Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom, ²Adelphi Real World, Manchester, United Kingdom, ³Adelphi Real World, Macclesfield, United Kingdom, ⁴Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ⁵Desarmen of Rheumatology, Unit Hospital Clinico Universitario, Santiago, Spain, ⁶Rheumatology, CHU Dupuytren, Limoges, France, ⁷University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁸Medical Affairs, Pfizer Inc, Brussels, Belgium, ⁹Pfizer Inc, Tadworth, United Kingdom, ¹⁰Global Health and Value, Pfizer Inc, New York, NY
Background/Purpose: Current recommendations for pharmacologic management of rheumatoid arthritis (RA) advise dose titration or switching treatment if goals of remission or low disease activity are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].